Augurex and Quidel are pleased to announce the launch of the JOINTstat® 14-3-3η RUO (research use only) ELISA. This new distribution arrangement will get 14-3-3η testing into the hands of more investigators worldwide, including key opinion leaders and pharmaceutical companies, to advance and grow the body of data for this novel joint damage biomarker in autoimmune diseases.
There is increasing international momentum to investigate the role of 14-3-3η in various autoimmune diseases with joint involvement. In addition to rheumatoid arthritis (RA) where the largest body of 14-3-3η data exists, conditions such as System Lupus Erythematosus, Inflammatory Bowel Disease and Psoriasis have a high incidence of arthritis, secondary to their primary autoimmune disease. 14-3-3η informs mechanistic joint damage processes common to these conditions allowing novel biochemical pathways and therapeutic options to be investigated from the basic science level, right through to disease prevention and controlled clinical remission.
For Augurex, the synergy with Quidel is their strong and growing bone and complement pathway marker business which has an excellent distribution fit for client groups interested in investigating 14-3-3η. “Most importantly,” commented Norma Biln, CEO of Augurex, “we are committed to working with companies who not only have commercial strength but also share similar guiding principles to ours, including integrity, patient focus and optimism. Ultimately this benefits all stakeholders, especially patients who are waiting for solutions.”
Please visit Quidel’s booth # 654 at ACR to learn more about their products and accessing 14-3-3η. The following 14-3-3η clinical studies with leading international investigators will be presented at ACR.
List of 14-3-3η ACR 2018 Conference Proceedings
Levels of 14-3-3η are an Independent Predictor of Long-Term Radiographic Erosive Progression and of Short-Term Rapid Radiographic Erosive Progression in Patients with Inflammatory Polyarthritis
Authors: Gilles Boire, Nathalie Carrier, Artur J deBrum Fernandes, Ariel Masetto, Sophie Roux, Norma K. Biln, Yuan Gui, Jane Savill, Sara Michienzi and Walter P. Maksymowych
Poster Number: 1454, Monday Oct 22nd 9:00 AM, McCormick Place, Poster Hall F2
Is 14-3-3η a Predictor of Development of Rheumatoid Arthritis in Patients with Early Undifferentiated Arthritis?
Authors: Karen Marie Carlsen, Nina Schmidt, Anne Duer, Kim Hørslev-Petersen, Cecilie Heegaard Brahe, Merete Lund Hetland, Norma K Biln, Michelle L Zaharik, Bo Jannik Ejbjerg, Lene Ba, Michael Sejer Hansen, Julia Sidenius Johansen, Hanne Merete Lindegaard, Jakob M. Møller and Mikkel Østergaard
Poster Number: 1482, Monday Oct 22nd 9:00 AM, McCormick Place, Poster Hall F2
Augurex is a Canadian biotechnology company focused on the development and commercialization of biomarkers that transform patient clinical management for better disease outcomes. The company brings innovative blood tests and digital health, near-patient solutions to market to better inform clinical assessments for more precise care. Along with its integral team of collaborators and world-renowned clinical opinion leaders, Augurex is transforming autoimmune patient management, from early diagnosis to monitoring, with its 14-3-3η biomarker portfolio of tests. In addition to these clinical applications, the 14-3-3η assay supports basic science and pre-clinical research to optimize drug development programs.
Quidel Specialty Products is the option for all your research, biosafety, and cytotoxicity testing needs. Quidel MicroVue products are a well-established name in immune system monitoring, assays for the assessment of Complement activation, as well as biochemical bone markers. Quidel offers products to meet biosafety testing and Complement dependent cytotoxicity testing needs, such as normal human sera, cobra venom factor and Complement fragment assays. ELISA assays, depleted sera, proteins, monoclonal and polyclonal antibodies, antisera, antigens, controls, and special reagents are also available to round-out a comprehensive laboratory portfolio.
Our mailing address is:
Augurex Life Science Corp
Suite 220 – 887 Great Northern Way
Vancouver, BCV5T 4T5